Testing JYB1904 injection for allergies in teens
Treatments studied
Part of Immune system & allergy clinical trials.
This study tests a new injection called JYB1904 to help adolescents with allergic diseases like food allergies, hay fever, allergic asthma, or chronic hives. Researchers want to learn if it's safe and how well it works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 12 and 18 years old
- You have a history of allergic diseases (such as food allergies, hay fever, asthma, or chronic hives)
- You weigh at least 30 kg (about 66 pounds)
- You agree to use effective birth control during the study and for 1 year after the injection
- You and your parent or guardian understand the study and can attend all visits
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new injection called JYB1904 for people with year-round nasal allergies. It may help reduce symptoms like sneezing, stuffy nose, and runny nose.
This trial tests a new injectable medicine (JYB1904) to see if it can reduce itching and hives better than standard antihistamines alone. If you have chronic hives with no clear cause and still get symptoms despite taking antihistamines, this study may be an option for you.
This trial tests a new medicine, JYB1904, for people with chronic hives (itching and welts) that haven't been controlled by standard allergy pills. It aims to see if JYB1904 can reduce itching and hives better.
This trial tests a new injection called GR1802 for people with seasonal allergic rhinitis (hay fever) that isn't well controlled by standard treatments. It aims to see if this medicine can help reduce symptoms during pollen season.
This trial tests a new allergy shot (ITI-9001) for people with Japanese cedar pollen allergy. It aims to see if the shot is safe and can reduce allergy symptoms. The study is for people who have not tried immunotherapy before.
This study tests a new epinephrine auto-injector (FMXIN002) compared to the standard EpiPen in people with a history of hay fever or seasonal allergies. The goal is to see if the new device works just as well and is safe in a controlled clinic setting.
Hear when a new Allergic Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.